Insmed Incorporated
Clinical trials sponsored by Insmed Incorporated, explained in plain language.
-
New inhaled drug aims to help PAH patients walk farther
Disease control Not yet recruitingThis study tests a new inhaled powder called treprostinil palmitil (TPIP) taken once daily to see if it helps people with pulmonary arterial hypertension (PAH) walk farther. About 344 adults with PAH will receive either TPIP or a placebo for 24 weeks. The main goal is to measure …
Phase: PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for lung patients: Long-Term safety trial of inhaled therapy begins
Disease control Not yet recruitingThis study looks at the long-term safety of an inhaled drug called treprostinil palmitil (TPIP) for people with pulmonary hypertension linked to interstitial lung disease. About 344 adults who finished a previous study will take the drug and be monitored for side effects and brea…
Phase: PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated May 11, 2026 20:38 UTC